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ABSTRACT 19 
 20 
This study considered the range of ethical issues and potential stakeholder priorities associated with 21 
the application of genomic technologies applied to animal production systems, in particular those 22 
which utilised genomic technologies in accelerated breeding rather than the application of genetic 23 
modification.   A literature review was used to inform the development of an ethical matrix, which 24 
was used to scope the potential perspectives of different agents regarding the acceptability of 25 
genomic technologies, as opposed to genetic modification (GM) techniques applied to animal 26 
production systems. There are very few studies carried out on stakeholder (including consumer) 27 
attitudes regarding the application of genomics to animal production in the human food chain and it 28 
may be that this technology is perceived as no more than an extension of traditional breeding 29 
techniques. While this is an area which needs more research, it would appear from this study that 30 
genomics, because it avoids many of the disadvantages and consumer perceptions associated with 31 
GM, is likely to prove a more publicly acceptable route than is GM for the development of healthier 32 
and more productive animals. However, stakeholders also need to have an approach to the moral 33 
status of the animals involved that finds credibility and acceptability with civil society.    34 
Keywords .  Genomic technology; Genetic modification; Animal production; Ethical matrix; 35 
Stakeholder;  36 
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INTRODUCTION 41 
 42 
The demand for animal derived protein is increasing, driven by continued global population 43 
growth, and rising incomes and urbanisation in developing and emerging economies (Boland et al, 44 
2013). At the same time, increasing levels of animal protein continued to be consumed in developed 45 
countries (Daniel, 2011). Increased demand raises questions about increased concern about 46 
production animal welfare standards associated with increasingly intensive animal production 47 
systems being introduced to meet societal requirements (Fraser, 2008). It has been argued that 48 
improved breeding technologies are required to deliver improved efficiencies in animal production 49 
systems, while at the same time ensuring optimal standards of animal welfare and environmental 50 
protection are maintained. In this context, animal welfare may be difficult to assess (Blokhuis et al., 51 
2003; Botreau et a.l, 2007), but should be taken into account when applying novel technologies to 52 
animal production systems. There has been considerable scientific and economic investment in 53 
developing scientific approaches to improved production animals (Mora et al, 2012), which may also 54 
deliver enhanced animal welfare through improved animal health (Rothschild and Plastow, 2007). 55 
Within this context, societal debate about if, and how, genomic technologies should be applied to 56 
animal production systems remains an area of (potentially controversial) discussion (e.g. see Fiester 57 
2008).  58 
Not least among the arguments presented in relation to the application of genomic 59 
technologies are those related to ethical issues, which may apply to consideration of the negative or 60 
positive impacts of genomic technologies on animal welfare (Pascalev 2006; Palmer 2012), economic 61 
factors such as impacts on the livelihoods of primary producers who adopt or do not adopt genomics 62 
utilised in animal breeding (Menozzi et al, 2012), or societal concerns about risks to human or animal 63 
health, the environment, or consumer choice regarding the products of such technologies  (e.g.  see 64 
inter alia Kaiser, 2005;  Frewer et al., 2013a). In addition, the use of genomic technologies for 65 
agricultural purposes is potentially less cost effective than for medical applications (e.g., Laible & 66 
Alonso‐González 2009), such that scientific and infrastructure investment may not deliver increased 67 
efficiencies in the supply chain proportionate to increased food security, or profitability for 68 
producers. From this, two issues of relevance to ethical debate can be identified. The first relates to 69 
whether investment in animal genomic technologies will deliver advantages to society, (including in 70 
terms of the welfare of the animals themselves), proportionate to the investment of resources, and 71 
production costs. The second relates to whether resource investment in genomic technologies in 72 
animal production systems at the expense of investment in other technological innovations will 73 
reduce future flexibilities in animal husbandry systems.  74 
Within this context, it should be recognised that not all genomic technologies applied to 75 
animal production systems are associated with the same ethical implications for producers and 76 
other stakeholders, including consumers. While the ethical implications of Genetic Modification 77 
(GM) applied to animal production have been considered extensively (e.g. see, inter alia, Lassen et 78 
al, 2006; Verhoog, 2003), genomic technologies which do not involve genetic transfers from one 79 
organism to another (see Rothschild and Plastow, 2007), have less frequently been considered. 80 
Many genomic technologies do not involve GM, but map rapidly and accurately the genome of 81 
production animals, which may be applied to improve production efficiency or animal welfare 82 
through selective breeding (e.g. Van Tassel et al., 2008; Womack, 2005). Examples include marker-83 
assisted selection to develop production animals which deliver improved meat quality (Rothschild 84 
2004; Gao et al, 2007), and single nucleotide polymorphism (SNP) associations to assess traits such 85 
as behaviour, disease resistance, and structural and environmental adaptivity, which may identify 86 
genetic causes for differences related to behaviour and stress. This may, in turn, facilitate the 87 
breeding of healthier, more adaptable animals and promote animal welfare (Rothschild and Plastow, 88 
2007). Improved feed efficiencies developed through genomic research may also reduce production 89 
costs (Kim et al, 2000). Ethical concerns may vary between different stakeholder groups, including 90 
primary producers, representatives of the food industry, non-governmental organisations (NGOs) 91 
with interests in environmental protection, consumer and animal welfare and health, as well as  92 
consumers (see, inter alia, Bremer et al, 2013; Marris, 2001; Kaiser et al, 2007).  It is the opinions 93 
and priorities of these stakeholders which will shape the success or otherwise of the implementation 94 
and commercialisation trajectories of genomic technologies applied to animal production systems 95 
applied within the agricultural and food sectors.  96 
The aim of the current paper is to develop an analysis of the ethical positions of different 97 
stakeholders regarding the application of genomic technologies to animal production systems. To 98 
this end, GM, which has been identified as potentially one of the most controversial of genomic 99 
technologies applied within the animal production  sector (McNaughten, 2004; Chapotin and Wolt, 100 
2007; Frewer et al., 2013b), will be compared with genomic technologies which do not involve  101 
genetic modification  102 
 103 
Ethical issues and regulation  104 
The literature suggests that societal responses to non-food applications of GM animals (for 105 
example, in relation to pharmaceutical production or as human or animal disease models) raise few 106 
societal objections assuming animal welfare standards and safety assessments are adequate and 107 
addressed in regulatory procedures; the latter is a de minimis requirement for societal acceptance of 108 
food-related applications od GM technologies to animals, although the purposes of the genetic 109 
manipulation, in particular in relation to specific  benefits and beneficiaries, appear to be the 110 
decisive factor in determining consumer acceptance (Frewer et al, 2013b).  While the ethical 111 
concerns of stakeholders (e.g. , members of policy communities, industry representatives and 112 
environmental and consumer groups) have been examined in this context (e.g. see Mepham 2000; 113 
Kaiser et al, 2007; Novoselova et al, 2007), less is known about the opinions of such key stakeholders 114 
and end-users regarding genomic technologies which do not involve genetic modification. 115 
Understanding such concerns is important from the perspective of optimising ethical standards and 116 
animal welfare issues in animal production systems, and  ensuring their economic viability,  which in 117 
turn will affect all actors in the supply chain. 118 
Important stakeholders with interests in genomic technologies applied to food production 119 
Animal health and animal welfare have been shown to be linked with the economic well-120 
being of farmers (Scott et al., 2001). While there is a societal perception that farmers are primarily 121 
financially motivated, and concerned only with their livelihood (Hubbard and Scott 2011), there is a 122 
large degree of variability between farms, and farmers differ considerably in how they make 123 
decisions regarding formulation of farming strategies (Siebert et al., 2006). Most farmers are 124 
interested in supplying high-quality products, having a satisfying job and establishing a more positive 125 
image of agricultural and livestock production. Thus it is important to understand how farmers 126 
conceptualise the impacts of genomics on production animals in terms of product quality and animal 127 
welfare, as well as economic demands on the supply chain, and compare this with consumer 128 
perceptions.   129 
Other ethical concerns may arise within the context of animal production systems. The need 130 
for improved food security (e.g. see, inter alia, Erikssen et al, 2014;  FAO, 1996; Godfray et al., 2010; 131 
Godfray and Garnett, 2014) is an important driver which influences the need for increased efficiency 132 
of animal production systems. The increased global demand for animal protein means that improved 133 
efficiencies need to be identified in animal production systems, unless demand reduces or 134 
substitutes are developed (GO-Science, 2011). Arguably, both delivering access to secure nutrition, 135 
or at least secure food comprising of the range of nutritional requirements, equitably distributed 136 
across the needs of global populations, represents an important ethical issue, as does reducing 137 
overconsumption and food waste, particularly in affluent countries. In this context, concerns about 138 
negative impacts on human health associated with increased animal protein production (Wang  and 139 
Beydoun, 2009; Boyd et al , 2011; Chao et al, 2005; Lutsey et al, 2008; Popkin  et al, 2012) and 140 
increased consumer demand, (Fuller et al; 2002; Godfray et al, 2010), must also be addressed. An 141 
ethical issue therefore relates to whether increasing supply of animal proteins may have a 142 
detrimental effect on the environment and on human health, through changed accessibility if supply 143 
increases outstrip demand or vice versa. Thus health care professionals represent an important 144 
stakeholder in the debate about genomic technologies applied to animal production systems, in 145 
particular if supply is increased, which may then subsequently increase consumer demand. 146 
Developing healthier products (for example, meats which are lower in fat or higher in important 147 
nutrients for human health) may contribute to improved public health, but costs may be too high for 148 
these products to contribute to anything other than a niche consumer market; another ethical issue 149 
is therefore is equity of access to the benefits of genomics technologies applied to animal production 150 
systems. Genomic information could be applied to breeding animals that are more environmentally 151 
sustainable, that have different meat nutritional profiles, that are more efficient or economically 152 
sustainable or that are more disease resistant. From an ethical perspective it may also become 153 
possible to use genomic information to select animals that make raising and handling animals easier 154 
for farmers, transporters and processors (animals that can more easily handle the stress of long 155 
transport for example). All of these possibilities come with ethical considerations – which attributes 156 
should be encouraged (or data provided allowing farmers to choose attributes) and how the choice 157 
of particular strategies will affect animals, farms and farmers, consumers and the public. What 158 
differentiates the use of genomic information is the speed at which the particular genes can be 159 
identified and the genetics of domesticated animals changed in a particular direction – which may or 160 
may not be to the benefit of society.   161 
Consumer perceptions and attitudes towards genomic technologies applied to animal production 162 
systems  163 
Consumer perceptions are potentially an important factor influencing the commercialisation 164 
trajectory of animals produced using genomic technologies. There has been considerable research 165 
directed towards understanding consumer perceptions associated with the acceptability of GM 166 
animals used for food production (e.g. see Costa-Font et al., 2008; Frewer et al., 2013a, 2014). The 167 
main conclusions can be summarised as follows. First, consumer perceptions or attitudes associated 168 
with GM animals applied in the agrifood sector are generally more negative than those associated 169 
with GM plants or other less advanced organisms, independent of in which region globally data are 170 
collected. In Europe, high levels of risk perception have lead to consumer rejection of GM animals 171 
applied to food production. In North America and Asia concerns focus on moral and ethical issues. 172 
However, consumer decision-making regarding the acceptability of different applications is 173 
contextualised by a case-by-case analysis of specific applications, including specific (perceived) risks 174 
and benefits, and other values, such as ethical concerns and values.  175 
However, research into consumer perceptions of, and attitudes towards, genomic technologies 176 
applied to production animals has less frequently focused on technologies which do not involve GM 177 
per se. Genomic technologies have infrequently been examined in the context of plant-related 178 
applications, and empirical studies involving accelerated breeding of animals are less frequent again. 179 
There is limited evidence to suggest that  consumer attitudes towards genomic technologies applied 180 
to plants which do not involve GM but rather involve other genomic technologies are viewed 181 
relatively positively by consumers (Schenk et al 2008; Van den Heuval et al. 2008).  182 
A limitation of current knowledge related to genetic technologies applied to animals utilised in 183 
food production is whether genomic technologies raise different ethical issues according to: 184 
1. Whether the technology applied is GM or other genomic technologies which do not involve 185 
GM. 186 
2. Whether different stakeholders, including consumers and/or citizens, perceive differences in 187 
ethical issues. 188 
3. Whether such differences in perception are linked to their membership of a specific 189 
stakeholder group (e.g. consumers, primary producers, industry). 190 
4. Whether 1, 2 and 3 are influenced by the outcome of the genomic application (e.g. animal 191 
welfare or improved production efficiency).  192 
 193 
Building on the overall objective of the paper, genetic technologies applied to production animals in 194 
general from the perspectives of different stakeholders and end users, including consumers, will 195 
now be considered.   196 
 197 
LITERATURE REVIEW METHODOLOGY 198 
A review of the literature regarding ethical issues and genomics applied to production animals was 199 
conducted.  The search terms are provided in table 1. The purpose was to extract ethics literature 200 
focused on both GM production animals, and those developed using other forms of genomic 201 
technology.  202 
…………………………….. 203 
Table 1 about here 204 
…………………………….. 205 
  206 
The research questions were as follows: 207 
1. What are the ethical issues associated with the application of genomic technologies to 208 
animals utilised in food production? 209 
2. Do these vary between application of GM, and other forms of genomic technologies applied 210 
to selective breeding? 211 
3. Do differences exist between applications used to improve animal welfare and feed 212 
efficiency? 213 
Two data bases, “Scopus” and “Web of Knowledge”, were searched1 .  The search terms were 214 
included in the topic section of the database, and in the keywords, title, or abstract of the article 215 
being searched. For quality control reasons, only peer reviewed articles published in English were 216 
included.  217 
The review process first considered the GM and genomic technologies identified in the 218 
papers and the extent to which ethical aspects of the technology had been considered. 219 
Impact of ethical and moral considerations on consumer attitudes 220 
                                                          
1
  The first search was conducted on 16 August 2013 in Web of Science, which yielded 72 relevant 
papers, and on 15 August 2013 in Scopus which yielded 88 relevant papers. After these lists were combined 
and duplicates removed, 127 papers remained for review. 
 The review process was then repeated with a particular focus on capturing stakeholder and 221 
citizen perceptions of use of both GM and genomics in agricultural animal production systems. The 222 
results were then combined and a critical analysis applied to map ethical priorities against the 223 
perspectives of specific stakeholder groups, as well as identify gaps in the existing literature. The 224 
information identified from the review was subject to ethical analysis through the use of an ethical 225 
matrix.   226 
The concept of the ethical matrix is to consider for modern technologies used in food 227 
production, how the fundamental ethical principles of autonomy (self-determination), non-228 
malfeasance (no harm), beneficence (“do good”) and justice (fairness), are applied to, and perceived 229 
by, various interest groups  (e.g., producers, consumers, and the biotic environment; Mepham 230 
2000). While acknowledging that this approach has limitations in analysing and weighing the ethical 231 
issues associated with a technology, it is helpful in identifying the types of issues that may need to 232 
be considered (Coles and Frewer 2013). A generic ethical matrix regarding the application of 233 
genomic technologies to food production animals was developed. The interest groups identified are: 234 
scientists and developers, farmers, food manufacturers and distributors, workers, consumers, 235 
animals and the biotic environment. In addition, the study seeks to identify whether any distinction 236 
exists in ethical concerns (including ethical concerns as perceived by the public) between the use of 237 
GM technology or other genomic approaches which do not utilise GM per se but instead use genetic 238 
technology to inform more efficient genetic selection. Two other relevant areas of ethical 239 
consideration, which do not fit neatly into the four ethical principles described above, but which 240 
nevertheless do raise ethical concerns amongst many stakeholders are those of “Unnaturalness”, 241 
and “Enhancement” or “Disenhancement”.  242 
Unnaturalness 243 
The concept of unnaturalness has been an area of concern for many years in relation to GM 244 
organisms in general but more strongly felt in relation to GM animals (see e.g. Bredahl, 1999; 245 
Tenbült et al, 2005). This can frequently be expressed as feelings that range from vague unease to 246 
disgust at the idea of creating animals that would not normally occur naturally, which may stem 247 
from religious beliefs, cultural or traditional norms and identity, perceptions of consumer health and 248 
environmental risks, animal welfare or simply the idea of changing the nature or affecting the dignity 249 
or telos of the animal. There is, for example, a feeling amongst some consumers that because it is 250 
“unnatural”, GM technology should not be utilised in developing or improving animal species, 251 
particularly within the food chain (Frewer et al, 2013a). While for some individuals this will arise 252 
from deeply held religious convictions that GM technology is somehow “interfering” with creation, 253 
for others it may have more to do with concerns about risk such as fears that science does not have 254 
adequate understanding of genetics and the possible unseen impacts of manipulating genes that 255 
would not occur naturally in animals, with the objective of ensuring that we do not generate 256 
irreversible damaging effects on the environment and its biota. However, the same feelings of 257 
“unnaturalness” may not apply to the application of genomics to what might be considered natural.  258 
Enhancement and disenhancement  259 
While feelings of unnaturalness may be associated with certain forms of GM applied to 260 
animals, it is also important to consider the ethical aspects of whether the use of such techniques for 261 
the enhancement of animals in order to improve their health and well-being is ethically problematic 262 
(Chan, 2009). The objective may be to improve productivity through reducing the incidence of 263 
disease, simultaneously benefiting the animal itself in terms of reducing suffering and distress. 264 
Consideration as to whether it is appropriate to adopt an instrumentalist approach to animals is 265 
required. This approach affords them no rights but considers their well-being solely in relation to the 266 
extent to which it benefits humans. Alternatively animals can be ascribed “moral status” whereby 267 
humans have a responsibility to treat animals well for their own sake and thus also consider 268 
enhancement in relation to whether it benefits the animal itself (Chan and Harris, 2011). 269 
Disenhancement could involve changing the animal in order to make it more compliant with 270 
particular production methods. In other words the concept of disenhancement has arisen to some 271 
extent as a possible solution to issues of animal welfare during their incorporation into the human 272 
food chain (Ferrari, 2012). Hence it has been suggested that if an animal’s welfare can be improved 273 
by GM so that any suffering can be reduced by, for example, reducing the animal’s ability to feel pain 274 
that is ethically acceptable (Thompson 2008). The animal does not suffer and is also compliant to 275 
more aggressive production methods. One example frequently quoted is that of “the blind chicken” 276 
(Thompson 2008). Chickens farmed intensively in battery conditions frequently attack each other, 277 
plucking the feathers from neighbouring chickens and so causing distress and suffering. However, 278 
chickens that are blind show little or no inclination to engage in this behaviour. It is therefore argued 279 
that to disenhance all chickens to make them blind will not only reduce the suffering of the chickens 280 
but also enhance the use of battery farming. However, from an ethical point of view, it is important 281 
to consider enhancement not only from a position of utility, or improvement of animal welfare. It is 282 
essential to also take into account the concepts of telos and dignity.  Here, the dignity of the animal 283 
and of humans who represent moral agents are included (Weckert 2012). If human beings adopt the 284 
approach that improving animal welfare through disenhancement will reduce suffering and so 285 
facilitate more profitable production, we are simply commodifying the animal and according it no 286 
intrinsic value whatsoever, but rather treating it only as an object for maximising profit (Palmer 287 
2011). Whilst animals may not be considered as moral agents, they certainly have particular states of 288 
being to which they aspire and which accord to them a certain dignity, including species-specific 289 
needs and possibilities (Kunzmann 2010). It has been argued that the extent to which we deny 290 
animals dignity and the ability to adopt states of being in which they would naturally choose to exist, 291 
reflects something of our own morality (Warkentin, 2009). The ethical matrix analysing ethical issues 292 
against stakeholder interests and priorities is presented in table 2. 293 
……………………………….. 294 
Table 2 about here 295 
………………………………. 296 
 297 
DISCUSSION 298 
The ethical perspectives of different stakeholders regarding genomics applied to animal 299 
production systems will be discussed in turn.  300 
Scientists and Innovators 301 
From an ethical perspective, scientists and innovators developing advances in both GM and 302 
genomics in animals in the food chain will see their role as not only pushing back the frontiers of 303 
scientific understanding, but also finding ways of improving food security and production efficiency 304 
through improving animal growth and resistance to disease and pests. Responsible researchers will 305 
aim to improve the welfare of the animal by reducing disease-related suffering. An environment in 306 
which scientists and innovators are free to investigate and pursue their scientific endeavours is 307 
considered to be extremely important by these stakeholders. However, while it is often argued that 308 
scientists should not be restricted in the way in which their research develops, it is clear that there 309 
are still limits of societal acceptability beyond which they should not go. The reality is that scientists 310 
not only have their work facilitated by the society within which they operate,  but that society also 311 
embodies a moral, legal and regulatory framework to which scientists and innovators should comply. 312 
Scientific research operates within a framework of committees on, for example, ethics and animal 313 
welfare, legislation on data and environmental protection as well as a wide range of other regulatory 314 
bodies. Scientists are also often seeking to develop innovations which they hope that society will 315 
adopt. Therefore not only is it in their interests in terms of the acceptability of the science to 316 
develop applications which are ethically acceptable, but they also have a responsibility to carry out 317 
their research in a way that minimises risks of harms to themselves, other stakeholders and the 318 
environment. It is important for scientists to be able to recognise not only where potential risks or 319 
hazards may lie but also consider the interests and perspectives of other current or future 320 
stakeholders. 321 
In comparing GM and genomic approaches  for improving animal productivity, health and 322 
welfare, the sustainability of the species gene pool is an important consideration. GM applications, 323 
including large scale cloning of successful modifications, entail some risk that pre-existing genes, if 324 
modified or excised from the genome, may eventually be lost from the entire gene pool. At the same 325 
time, novel or modified genes may be introduced, resulting in a significant alteration to a gene pool 326 
that has developed over millennia to withstand a wide range of environmental changes. With 327 
genomic solutions, however, the focus is on more accurate identification of individual genes and 328 
their expression, and better understanding of their specific functions either individually or in concert 329 
with other genes. Therefore, while such innovations may alter the balance of the gene pool, they are 330 
unlikely to eradicate completely the presence of any individual gene and will only make use of pre-331 
existing genes in developing strains that are more resistant to disease, more productive, more 332 
nutritious etc. However the speed at which the genetic selection could advance does necessitate 333 
some caution in order not to homogenize the domestic population of any livestock species. 334 
Measures to ensure preservation of the gene pool are essential for sustainability, and to minimise 335 
any risk of irreversible adverse effects. It is relatively easy to preserve the gene pool of plant species 336 
(e.g. see, for example, the Svalbard Global Seed Vault2, located in the permafrost in the mountains 337 
of Svalbard in Norway). It is much more costly and technically challenging to store animal genetic 338 
resources (see the National Center for Genetic Resources Preservation (NCGRP)3 in the USA). 339 
Therefore it might be argued that where a genomics solution for animal productivity, health or 340 
welfare is feasible, this would be a preferable to pursuing a GM solution even if only on the grounds 341 
of sustainability.  342 
Primary Producers (Farmers) 343 
While farmers farm in order to make a living, for most there are also many other factors 344 
which motivate them, not least of which are genuine concerns for the health and welfare of their 345 
animals beyond the need to provide fit and healthy specimens for the food chain. Farmers have a 346 
                                                          
2 http://www.regjeringen.no/en/dep/lmd/campain/svalbard-global-seed-vault.html?id=462220, 
accessed 14th May 2014 
3 http://www.ars.usda.gov/main/site_main.htm?modecode=54-02-05-00, accessed 14th May 2014 
strong interest in their ability to benefit from the introduction of a new technology through a 347 
positive impact on their productivity and hence profitability and the effect of the technology on the 348 
health and welfare of their livestock and the environment in which they live and work. It is important 349 
for those who are developing biotechnology applications for animals in the food chain to understand 350 
the factors which motivate farmers, and the relationship that they have with their livestock. This will 351 
enable them to identify those risks and benefits which are important to farmers and which influence 352 
their decision-making. These may include the quality of the product, their willingness to utilise less 353 
expensive, and/or lower quality feed and their priorities for animal health and welfare.  354 
A further issue likely to be of great importance to farmers is the extent to which they have 355 
autonomy and flexibility in relation to selection of the animals they choose to breed. This will include 356 
the impact of IPR and patenting of specific breed lines on the flexibility they have to breed 357 
subsequent generations, or to modify the genome of their stock. Will they face restrictions on 358 
breeding of “genomically bred” animals, or of crossing them with other varieties? How much 359 
information will be made to farmers? Genetic information is extremely powerful and valuable 360 
knowledge. Asymmetric information in any 'market' allows for the possibility of control and 361 
exploitation. Breeding companies and breed societies have historically been heavily involved in the 362 
development of phenotypic databases and this is likely to continue and indeed increase with 363 
genomic databases. However the genomic databases will be more powerful and as all genes contain 364 
information, every bit of research adds more knowledge about different links between genes, 365 
disease, efficiency etc. Therefore the level of information provided to farmers about an animal’s 366 
genome is particularly important and affects the amount of autonomy they have in breeding 367 
decisions. To a certain extent the provision of information directly to farmers will depend on who 368 
manages the databases and how those databases are linked to commercial transactions related to 369 
semen and animals to be used in breeding. If the decision rests purely with the owner of the 370 
databases, who may also be the suppliers of specific products (semen or animals), there can be 371 
asymmetric information and potential for market power. The ability to map the genome of 372 
domesticated animals ensures enormous amounts of data are available, which could be 373 
overwhelming if provided without filter to individual farmers. As understanding of the potential of 374 
the use of genomics grows the maximum social benefit from the technology will be achieved if data 375 
can be made available on demand for producers to optimize their own breeding decisions (Berry et 376 
al, 2014).   377 
Manufacturers and Distributors 378 
What ethical issues are relevant to the manufacturers and distributors responsible for 379 
processing, preparing, packaging and distributing animal food products to the consumer? Most 380 
obviously manufacturers and distributors should be provided with sufficient information to enable 381 
them to decide whether or not they wish to make use of suppliers using either GM or genomic 382 
technologies, and would expect to benefit from their trade in terms of profitability and promotion of 383 
brand identity. They will therefore be looking for an appropriate balance between quality and price 384 
that enables them to make a sustainable profit. This will be greatly enhanced by reliability of product 385 
quality and price. Acceptance of animal material produced from either GM or genomic technologies 386 
is therefore only likely if it can be demonstrated that there is a significant improvement in reliable 387 
quality over traditionally bred animals, particularly if the new technologies involve higher cost. A 388 
lower than normal cost might encourage adoption, assuming quality is equivalent. Ethically 389 
responsible members of the food industry will also wish to ensure that any animal products they 390 
utilise are produced using the highest possible welfare standards and involve production methods 391 
that minimise damage to the environment. This also impacts on their responsibility to the consumer 392 
where justice (fairness) requires that they are as open and transparent with consumers as possible, 393 
while at the same time preserving their own right to remain commercially competitive. Ensuring that 394 
their suppliers engage in good animal welfare and environmental protection standards is an ethical 395 
position for the food industry to adopt. It also makes commercial sense as utilising animal products 396 
from sources with poor animal welfare or environmental standards can seriously or even terminally 397 
damage brand image. Thus the industry will be acutely aware of the extent to which consumers are 398 
likely to accept or reject a new technology. The industry also has not only an obligation to meet 399 
regulatory requirements, but also an ethical responsibility in providing the consumer with adequate 400 
and appropriate information in order for them to exercise their autonomy in order to make 401 
informed choices about whether or not to purchase a particular product. This involves not only 402 
providing an accurate description of the product itself, (and any scientifically proven benefits), but 403 
also clear and understandable labelling to enable the consumer to identify what the product 404 
contains, from where it was sourced, details that may be relevant to the consumer about how the 405 
product was produced or sourced (e.g. free-range, caged, fair trade etc.) as well as any potential 406 
risks that may be associated with the product (such as and allergens that it may contain). Such labels 407 
often also benefit the manufacturer by acting as a means of advertising adherence to practices of 408 
which the consumer approves. As it would be ethically unacceptable for the food industry itself not 409 
to know whether its sources of animal material were utilising GM or genomic technologies, the same 410 
ethical principle applies in their responsibility to the consumer. It is important in relation to new and 411 
innovative technologies for consumers to be able to decide whether or not to purchase foods which 412 
involve the use of GM or genomic technologies in the food chain.  413 
One difference between the use of genomic information and GM lies in the ability of 414 
processors and retailers to require genetic information on the animals they purchase (particularly 415 
attractive as the cost of genotyping comes down). Animals bred based on genomic information for 416 
particular traits such as feed efficiency or disease resistance, for example, could be verified with 417 
genetic tests on the meat. This significantly increases the potential of traceability (currently back to 418 
location of origin) to also provide verification of genetic attributes of particular meat products. It is 419 
possible to imagine a particular retailer suggesting that their meat (beef, for example) is all produced 420 
from cattle verified to have a feed efficiency gene and thus produced with xx% less feed and xx% 421 
lower greenhouse gas emissions as a result. This could become a marketing edge for certain 422 
products and provide incentives for farmers to genotype more of their animals or select semen or 423 
breeding animals on the basis of specific genes.  424 
Workers in primary production and the food industry 425 
Those working in the food industry should expect the normal health and safety 426 
requirements to apply to their employment. This should include any additional measures in the case 427 
of GM to ensure that they are not exposed to any additional hazards such as retroviruses or 428 
zoonoses. They in turn have an ethical responsibility to ensure that they maintain high standards of 429 
animal welfare and environmental protection in their daily work and comply with all the relevant 430 
codes and regulations. No differences between GM and genomic technologies applied to animal 431 
production systems are identifiable in this regard.  For farmers and employees in 432 
processing/distribution/retailing of food or meat products the use of GM animal products or the use 433 
of products from animals created using genomic information is likely not much different. However 434 
the use of genomic information can provide additional verification of attributes of animals or meat 435 
products. Genetic tests can verify the presence or absence of GM in the product. The use of genomic 436 
information in breeding decisions cannot be verified as easily but the presence/absence of specific 437 
genes can be ascertained by genetic testing on animals or meat products. The understanding of the 438 
genome of domestic animals can provide additional assurances for farmers and employees that the 439 
animals/products they are working with are safe to work with.  440 
Consumers 441 
Those involved in development, production and supply of food at all stages of the human 442 
food chain have particular ethical responsibilities towards the consumer as the end-user of the food 443 
product. It is not enough to simply provide food that meets legal and regulatory requirements on 444 
food safety, it is also important that the information provided is fair both to themselves and to the 445 
consumer and adequate to enable consumers to make an informed choice. Consumer choice is 446 
made within a complex framework of their appreciation and understanding of risks, both technical  447 
and perceived, and influenced by the interaction of a wide range of values which may be derived 448 
from moral, societal, cultural, religious or personal preferences and perspectives including dietary 449 
choice. Therefore labelling of foodstuffs is essential for more than just safety reasons. In order to 450 
exercise autonomy of decision, consumers also need information on the geographical and biological 451 
source of the food together with the process by which it is produced and quantities of constituents. 452 
They will, in most cases, also require certain assurances about the food, such as welfare standards, 453 
how an animal is slaughtered, “naturalness”, whether it is produced organically and possibly factors 454 
relating to pay and working conditions of those involved in production. 455 
 In many countries, there is a requirement to label all GM products or indeed products 456 
produced using GM technology at some stage in the process. Other regulatory regimes have 457 
adopted the approach that it is not necessary to label GM products, based largely on the principle of 458 
substantial equivalence, and as a result GM food materials may be freely mixed with their non-GM 459 
equivalents. This approach however does deny choice to those consumers who do not wish to 460 
consume GM produce and could be criticised by some as ranking scientific opinion and commercial 461 
interest above consumer values and autonomy. Genomic technologies currently have no regulatory 462 
requirements for labelling or other identification or acknowledgement of use of this technology in 463 
the production of food, whether plant or animal. In most cases this is understandable as the animal 464 
product would be actually equivalent to produce from an animal bred by natural processes without 465 
the use of sophisticated genomic technology. However, it can be argued that consumers should be 466 
informed if the process involved any form of disenhancement or other animal welfare issue or 467 
indeed results in the use of any practices or processes that might be damaging to the environment 468 
such as increased use of pesticides, hormones, non-veterinary use of antibiotics, or other 469 
pharmaceutical products, or to the genetic diversity of domesticated animals. Traditional livestock 470 
breeding using quantitative genetics has never been an issue communicated to the public. On that 471 
basis the ‘equivalence’ of genomic selective breeding might not need to be communicated. The 472 
question of whether this will continue to be satisfactory to a public increasingly concerned about 473 
production technology remains open.  474 
Most consumers are unlikely to choose a food product resulting from novel technology 475 
unless they perceive that it provides some additional benefit to them compared to an equivalent 476 
“natural” product. They are even less likely to choose it if they perceive that there is any additional 477 
risk involved and are likely to be concerned if they perceive that any benefits accrue to others 478 
particularly commercial interests, while they bear any risk. Hence those seeking to introduce a new 479 
technology must to enter into dialogue about consumer concerns and priorities.  This may apply to 480 
novel genomic technologies, but research is needed to determine whether this is indeed a consumer 481 
priority in  the area of animal production systems.  482 
Issues for the environment 483 
Indeed the environment can be, and is, considered by many to be a system or “entity” 484 
consisting of all the interactions between all forms of life and the non-living materials that surround 485 
them. It may refer to a localised system or “ecosystem” , or be considered as encompassing all life 486 
on earth.  The environment is a stable system which can be disrupted by, and will, respond to the 487 
introduction of new factors whether living or not.  All life on earth interacts with, and depends upon, 488 
a stable environment such that changes to that environment which can affect its balance. Thus the 489 
ethical principles that apply to other stakeholders can also be analysed in relation to the 490 
environment, and similar regulatory controls implemented.    On one hand, it is arguable that non-491 
naturally occurring genomic technology may militate against the interests of the environment. 492 
However, in terms of societal responses to the implementation of different genomic technologies, it 493 
may be that  societal stakeholders will argue that the environment is better equipped to “adapt” to 494 
genomic technologies which have the potential occur naturally, as opposed to those which can only 495 
occur through human intervention.  496 
The following two cases identify some of the ethical implications identified in relation to the 497 
different biotechnology approaches in relation to, first, animal health and welfare and, second, feed 498 
efficiency 499 
GM versus genomic selection of pigs to improve health and welfare through improved disease 500 
resistance4. 501 
 502 
The ethical aspects of GM versus genomic selection in pigs for improving health and welfare 503 
through improved disease resistance need to take into account the motivation of scientists, breeders 504 
and primary producers  for seeking to improve porcine health and welfare. A question arises as to 505 
whether the objective is to improve productivity by reducing disease incidence, suffering and stress 506 
in the animals, or to enhance the quality of life of the animal and farmers or both.  The perspective 507 
on the moral status of the animals concerned will affect how the risks, benefits and ethical concerns 508 
associated with each technology are balanced.  509 
Other GM approaches which involve manipulation or alteration of genes may enable the 510 
development of new lines which are more productive, able to digest lower quality foods without 511 
adverse effects, resistant to common pests and diseases, or have specific genetic disorders or 512 
predispositions removed entirely from the genome. However GM technology still carries 513 
considerable risks in that the process of insertion of genes is not perfect and the outcome often 514 
uncertain (as demonstrated by the case of the Beltsville pigs in the US in 1985), which can result in 515 
further adverse welfare issues for the animal as well as incurring additional costs (Christiansen & 516 
Sandoe, 2000; Pascalev, 2006). The impact of alteration of the gene pool through removal or 517 
addition of specific genes also has to be considered as a sustainability issue. The commercial viability 518 
of GM animals in the food chain is also questionable as there is considerable evidence that even 519 
some consumers that accept GM technology in plants still have concerns of morality or 520 
                                                          
4
 An example research project is the Application of genomics to improve swine health and welfare project  
(http://www.swineimprovement.com/). The international project aimed at identifying genes related to disease 
susceptibility for two major global diseases in pigs has numerous objectives such as the potential for reducing 
antibiotic use in pigs, enhanced quality of pig life through disease resistance and reduced emotional and 
economic costs for producers. The possibilities for identifying the specific combinations of genes that identify 
disease susceptibility are limited, due to complexity and issues related to heritability. In this project an 
international multidisciplinary consortium of researchers is attempting to combine information and analytical 
tools to identify specific areas of the genetic code to focus on for these diseases. As the research advances it 
may become possible to select animals with higher levels of disease resistance in breeding reducing the 
incidence of the diseases globally. 
unnaturalness about use of GM technologies, particularly in the food chain. Even if the technology is 521 
applied primarily to improve porcine health and welfare, it is unlikely to be acceptable to consumers 522 
if they see no benefit to themselves from the technology.  523 
However, genomic technologies, informed by state of the art gene sequencing and genomic 524 
analysis of gene function and interaction, can use natural breeding processes and selection to rapidly 525 
develop better strains of pig with greater resistance to disease, reduce suffering and improve 526 
welfare (allowing artificial insemination to be considered as natural in this context). This avoids 527 
many of the actual or perceived disadvantages and uncertainties associated with GM technologies, 528 
including issues of morality, unnaturalness and sustainability. However, some current “natural” 529 
breeding programmes have resulted in negative outcomes in terms of animal welfare (e.g. breeding 530 
for productive efficiency in milk yield has resulted in reduced fertility in dairy cows (Oltenacu and 531 
Broom, 2010) and breeding programmes in poultry have resulted in musculoskeletal problems in 532 
poultry (Hocking, 2014). Therefore as use of advanced genomics is expected to rapidly speed up the 533 
process, it may be that there should be some mechanism to ensure positive animal welfare 534 
outcomes alongside development of other characteristics. As Hocking (1994) points out there is a lag 535 
between the development of breeding animals with optimal combinations of production, welfare 536 
and fitness traits and the adoption of such birds in commercial flocks, as for other livestock 537 
industries. The question of the moral status of the animal, and hence the motivation for use of 538 
genomic technology would still need to be considered. Hocking suggests the understanding of the 539 
genome of domesticated animals and the use of multiple indicators for selection possible through 540 
genomics may make the development of animals with production, welfare and fitness attributes 541 
easier than in the past when selection was based  on single traits.  However, it is worth noting that in 542 
domestic animals such as cats and dogs, breeding has for generations focussed on producing animals 543 
with characteristics which humans find pleasing, even when this results in breeds which have 544 
increased susceptibility to serious health issues. A greater awareness of the moral status of the 545 
animal for its own sake might therefore come to have implications beyond agriculture.  546 
Production efficiency and improved food security: GM versus genomic selection of cattle for feed 547 
efficiency 5.  548 
As in the previous example, consideration has first to be given to the moral status of the 549 
animals (cattle in this case). Here the objective is overtly about increasing production efficiency and 550 
the wider aim of improving food security. Hence a more utilitarian approach might be taken as 551 
ethical justification for altering the genome of the cattle in this case, as the outcome, even if it 552 
results in little health and welfare benefit for the cattle themselves, could be considered to not only 553 
provide greater profitability for the food industry through animals increasing in muscle mass and less 554 
fat and/or utilising lower quality feed more efficiently, better quality food for the consumer and 555 
greater food security for human society. It could therefore be argued that the overall net benefit is a 556 
greater good, even if there are less positive consequences for the cattle themselves in terms of 557 
animal health and welfare. So although GM technologies may involve higher costs and also carry 558 
greater risks both to the animals and in terms of gene pool sustainability, they might be considered 559 
as being appropriate in this case if the overall benefits are sufficient. However, as the overriding 560 
objective is to increase the quantity and possibly quality of meat entering the food chain, attempting 561 
to do this through the application of GM technologies would be completely negated unless 562 
consumer perceptions of unnaturalness and the idea of interfering with nature are allayed. A crucial 563 
factor in this would be for consumers to be able to identify clear and substantial societal and 564 
preferably personal, benefits in consuming food from GM animals and to be enabled to choose 565 
whether or not to consume GM food.  566 
                                                          
5
 An example research project is “ Whole genome selection though genome imputation of beef cattle”.  
(http://www.genomecanada.ca/medias/pdf/en/whole-genome-selection.pdf). The research involves the 
development of low cost tests which will allow the inferences of an entire genome from a relatively small 
number of genetic markers in cattle, providing breeding information at an early age. The research aims to 
improve production efficiency in cattle through improved feed efficiency.  
It would still appear that the ethical case is stronger for the application of genomics to 567 
improve production efficiency and food security, particularly if it is found that public concerns about 568 
unnaturalness do not apply to this technology as they do to GM. The risk issues to the animals would 569 
also appear to be less, and issues of gene pool sustainability are avoided. However, as for the 570 
previous case, some safeguards need to be in place to prevent adverse animal welfare effect and 571 
promote positive outcomes. There would then appear to be a better balance of risks and benefit 572 
between producers, consumers and the animals themselves. So a utilitarian ethical analysis might 573 
conclude that the net benefit of improving production efficiency and food security is greater using 574 
genomic technology than it would be using GM, assuming the same benefits can be delivered.  575 
CONCLUSIONS 576 
It is evident that increasing concerns over food security and animal welfare require solutions 577 
that improve production efficiency and also address issues of animal health and welfare within the 578 
human food chain. Gene technologies have developed to the point where they have the possibility 579 
to provide solutions. Important considerations that have to be taken into account are those of 580 
effective assessment of risks (to human health, animal health and welfare, the environment and 581 
economic viability), public acceptability and perceptions including moral values, as well as an 582 
awareness of the ethical basis of our treatment and usage of animals in the food chain.  Research 583 
has indicated that while there is little evidence that food derived from GM animals would provide 584 
any additional risks to human health,  there are still significant unknowns as well as potential risks to 585 
the health and well-being of the animals involved. In addition, there remains considerable consumer 586 
unease about the application of GM technology to animals used in the human food chain. There are, 587 
however, very few studies carried out on stakeholder (including consumer) attitudes regarding the 588 
application of genomics to animal production in the human food chain and it may be that this 589 
technology is perceived as no more than an extension of traditional breeding techniques. While this 590 
is an area which needs more research, it would appear from this study that genomics, because it 591 
avoids many of the disadvantages and consumer perceptions associated with GM, is likely to prove a 592 
more publicly acceptable route than is GM for the development of healthier and more productive 593 
animals.  It is also important that all stakeholders in the use of animals in the food chain have a 594 
better understanding not only of how they address the ethical issues that apply to their own area of 595 
activity but are also aware of those affecting other stakeholders. They also need to have an 596 
approach to the moral status of the animals involved that finds credibility and acceptability with civil 597 
society.    598 
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